Introduction
The poly(ADP-ribose)polymerases (PARPs) comprise a superfamily of enzymes which use NAD + to generate electrophilic ADP-ribose units to attach to substrate proteins to build polyanionic poly(ADP-ribose) polymers. 1 Two of the isoform members of this superfamily, the archetypal PARP-1 and PARP-2, detect sites of damage in DNA and use this poly(ADPribosyl)ation to open the chromatin structure and initiate and regulate repair of DNA. [1] [2] [3] Other members of the superfamily (e.g. PARP-3, PARP-4 (vault mPARP) and PARPs-5a,b (the tankyrases) have other regulatory functions within the cell. [1] [2] [3] [4] [5] [6] Inhibitors of PARP-1 are in clinical trial for the treatment of cancer [7] [8] [9] and have demonstrated beneficial activity in experimental models in a range of other therapeutic applications, including inflammation, 10, 11 organ damage following ischaemia-reperfusion, 12, 13 neurological damage, 14, 15 organ transplant 16 and multiple sclerosis. 17 The known pharmacophore for optimum inhibition of PARP-1 comprises a lactam fused to an aromatic ring (e.g. quinazolin-4-one, isoquinolin-1-one or phthalazin-1-one) or a similar primary benzamide where the conformation of the C=O-NH is held in the plane of the benzene ring by an intramolecular hydrogen bond. This benzamide amide motif is required for hydrogen bonding to the conserved Gly 863 and Ser 904 and -stacking with Tyr 907 in the (NAD + )-nicotinamide-binding site. The clinical candidates olaparib 1, veliparib 2 and rucaparib 3 ( Figure 1 ) fit this model. 5-Aminoisoquinolin-1-one (5-AIQ, 4, Figure 1 ) is an inhibitor of PARP-1 and PARP-2, which is highly water-soluble as its hydrochloride salt. Interestingly, 4 shows potent therapeutic activity in models in vivo of a range of diseases and disorders, including haemorrhagic shock, 18 myocardial infarction, 12 colitis 19 and cerebral ischaemia. 15 In the context of cancer, it inhibits angiogenesis 20 (PARP-1 regulates NF-B) and is potently antimetastatic, 21 inter alia. Exploring the structure-activity relationships around this core, we have reported that 4-aryl-5-AIQs and 5-benzamidoisoquinolin-1-ones are isoform-selective inhibitors of PARP-2. 22, 23 6-Arylthieno [3,4-c] pyridin-4(5H)ones inhibit PARP-1, 24 so we proposed that the analogous 3-substituted-5-AIQs should be explored.
We have previously reported the synthesis of 4 by condensation of methyl 2-methyl-3-nitrobenzoate with dimethylformamide dimethyl acetal (DMFDMA) to give 5-nitroisocoumarin, followed by conversion to 5-nitroisoquinolin-1-one with ammonia and reduction of the nitro group. 18 However, this method could not be extended to the 3-methyl analogue 25 and extension to the 3-aryl analogues was precluded by difficulty in accessing the required benzamide acetals. 3-Aryl-5-nitroisocoumarins 5 have been accessed by CastroStevens coupling of 2-iodo-3-nitrobenzoic acid 6 with arylethynes, followed by cyclisation in situ (Scheme 1) but this process was limited to three examples. 26 Sonogashira coupling of methyl 2-iodo-3-methylbenzoate 7 with phenylethynes was investigated, followed by cyclisation with Hg 2+ as catalyst but this was only effective for one example (R 3 = Ph). 26 A more general but low-yielding method involved Friedel-Crafts acylation of 5-nitroisocoumarin 9 with aroyl chlorides under forcing conditions in nitrobenzene, followed by in situ rearrangement and decarboxylation; this was limited to benzoyl chloride and aroyl chlorides carrying electron-withdrawing para-substituents. 27 There is therefore a need for a more general route to 3-substituted-5-nitroisocoumarins and, hence, to 3-substituted analogues of 4.
In 1929, Hurtley reported the displacement of the halogen from 2-bromobenzoic acid with the enolates of -diketones and of -ketoesters in the presence of copper catalysts to form the corresponding arylated -dicarbonyl compound. 28 He noted "The presence of copper-bronze or copper acetate is necessary; the latter appears to be the more vigorous catalyst, but the former gives purer products and was used where possible." Later mechanistic studies have not proved fully conclusive. 29 Most have determined that the carboxylate of the aryl component is essential and that bromine is the optimum halogen. 29, 30 Ames and Ribeiro extended this process by forcing a retro-Claisen condensation and ring closure on the Hurtley products with sodium chloride at 170C to give isocoumarins in moderate yields, making the 3-substituted isocoumarins available in two steps from 2-bromobenzoic acid and pentane-2,4-dione or 1,3-diphenylpropane-1,3-dione. 31 Very recently, Cai et al. developed a one-pot synthesis of 3-substituted isocoumarins by reaction of 2-iodo-or 2-bromobenzoic acid with -diketones, catalysed by copper(I) iodide and potassium phosphate in dimethylformamide under forcing conditions in a sealed tube. 32 No 5-substituted analogues were reported. This tandem process has been extended to use of 2-iodobenzanilides, in place of 2-bromobenzoic acid, but Kavala et al. note that isocoumarins carrying nitro groups are unstable to the reaction conditions. 33 We therefore sought to expand the tandem Hurtley -retro-Claisen -cyclisation reaction to the one-pot synthesis of 5-nitro-3-substituted isocoumarins without recourse to sealed tubes.
Results & Discussion
2-Bromo-3-nitrobenzoic acid 10 (Scheme 2) was prepared by mercury-catalysed decarboxylation of 3-nitrobenzene-1,2-dioic acid (3-nitrophthalic acid), followed by treatment of the intermediate aryl-mercury with bromine, 34 by analogy with our previous method for 2-iodo-3-nitrobenzoic acid. 26 Many of the -dicarbonyl components were commercially available but Claisen condensations, either base-catalysed (sodamide) or Lewis-acid catalysed (boron trifluoride.acetic acid complex), were used to supply others.
As a preliminary study to establish suitable reaction conditions for the reaction, 10 was treated with the trifluoromethylphenyl -diketone 11a, using Hurtley's original reaction conditions (copper powder, with sodium ethoxide as base in boiling ethanol) 28 (Scheme 2). The isocoumarin 12a was isolated in modest yield, through a tandem Hurtley -retro-Claisen -cyclisation sequence. The mono-ketone 13 and the ester 14 were also obtained as by-products. Interestingly, there was no evidence for formation of 3-methyl-5-nitroisocoumarin, arising from an alternative retro-Claisen reaction in the sequence, nor were the intermediate arylated diketone 15 Replacement of the base with the less nucleophilic potassium t-butoxide and the solvent with t-butanol obviated the premature retro-Claisen cleavage (Scheme 3), providing mixtures of the required 3-substituted 5-nitroisocoumarin 12a-h and the 3-methyl analogue 12g, arising from an alternative retro-Claisen cleavage as the second step. These were readily separated by column chromatography. As shown in Table 1 , the yields of 12a-h were poor-to-modest. Rationalising that material was being lost through the alternative retro-Claisen cleavage of the R 3 CO group, we examined the tandem Hurtley -retro-Claisen -cyclisation reaction sequence with symmetrical -diketones 17b,d,h-k (Scheme 4). As for the unsymmetrical analogues 11, Interestingly, during the assembly of the dibenzyl symmetrical -diketone 17i from ketone 18 and ester 19, a quantity of the homo-Claisen product 20 was also formed, reflecting the acidity of the -protons in the intended electrophilic component 19 (Scheme 4). The yields of the required 3-alkyl and 3-aryl 5-nitroisocoumarins 12 were markedly higher when the symmetrical diketones were employed (Table 1) , using the same reaction conditions (potassium tbutoxide in t-butanol). In cases where both methods were examined for the same target 12a,d,h, the yield for the tandem reaction with the symmetrical diketones 17 was much higher. Indeed, the yields exceeded the sums of the yields of (desired isocoumarins + 12g), suggesting that not only was the problem of the wrong acyl group being lost in the retro-Claisen step being resolved but also that the initial Hurtley reaction was proceeding better with the enolates of 17. The dialkyl symmetrical -diketones 17g-k gave lower yields than the diaryl analogues 17b,d.
Thus the tandem reaction provided sufficient quantities of the isocoumarins 17a-k for the remainder of the reaction sequence. Notably, the sequence proceeds with alkyl -diketones and with aryl groups carrying electron-neutral, +M and -I para-substituents but it fails completely with -M substituents on the aryl group, such as nitro and cyano.
The 5-nitroisocoumarins 12 were readily converted into the corresponding 5-nitroisoquinolin-1-ones 21 by reaction with ammonia in boiling 2-methoxyethanol (Scheme 5), obviating the use of sealed tubes for the more usual transformation in ethanol. The yields were mostly good-to-high. Reduction of the nitro group to furnish the target 3-substituted 5-aminoisoquinolin-1-ones 22 was effected with tin(II) chloride. For one example, 21a, catalytic hydrogenation was also explored but gave practical problems of separating the product 22a efficiently from the catalyst.
Biochemical evaluation
All the hydrochloride salts of 5-aminoisoquinolin-1-ones 22a-k showed good water-solubility (>1% w/v; > 30 mM). Each was evaluated in vitro for activity against human PARP-1 isolated from HeLa nuclear extract, using the KuDOS FlashPlate scintillation proximity assay method. 35 This isotopic assay measures PARP-1 activity through synthesis of
Tritium bound to the FlashPlate was counted using a scintillation plate reader. In this study, five different concentrations of the inhibitor, in a range surrounding the predicted IC 50 value, were used. Three independent determinations were performed for each candidate inhibitor 22a-k; the mean IC 50 values are reported in Table 2 .
In this assay, the mean IC 50 value for PARP-1 inhibition by the lead compound, 5-AIQ 4, was found to be 1.6 M, which is higher than that reported previously by us 36 for an assay in a broken nuclear preparation (300 nM) and that reported by Suto et al. 37 (250 nM) from a calfthymus preparation assay. Differences in absolute values of IC 50 between assay types are well known for PARP-1 inhibition. All the 3-substituted 5-aminoisoquinolinones inhibited PARP-1 activity, with many having IC 50 values in the 0.2-1.0 M range. Indeed, all except 22f,i were more potent than the lead compound 4. Generally, the simpler 3-alkyl compounds 22g,h,j were slightly more potent than the 3-phenyl compound 22b; this is in line with similar effects noted by White et al. 38 that 8-methoxy-2-methylquinazolin-4-one is ca. 5-fold more potent than is 8-methoxy-2-phenylquinazolin-4-one. Introduction of branching in the 3-alkyl chain, in the isobutyl analogue 22k and the benzyl analogue 12i, however, caused some loss of activity. A phenyl substituent is accepted at the 3-position (in 22b), showing that steric bulk is unlikely to be the simple explanation of the weaker activity of 22i,k. Curiously, the introduction of a thiophene ring at the 3-position resulted in a loss of potency in 22f, despite the usually accepted pharmacoequivalence of benzene and thiophene.
Selected compounds were also assayed for their inhibition of PARP-2 activity (Table 2) , using the assay previously reported by us. 23 Most of the analogues tested showed slightly greater potency against PARP-2 but the selectivity was not large enough to allow use in biochemical studies as selective inhibitors.
Molecular modelling studies
The structures of the 3-substituted 5-AIQs 22a-k were overlaid with the structure of the known inhibitor 8-hydroxy-2-methylquinazolin-4-one bound into the NAD + -binding site of the catalytic domain of chicken PARP-1 derived from co-crystal X-ray data retrieved from the Brookhaven Protein Data Bank (PDB code: 4PAX), using Tripos Associates SYBYL software on a SGI Octane II workstation. The 3-substituted 5-AIQ derivatives were initially positioned such that the central rings were overlaid with the 8-hydroxy-2-methylquinazolin-4-one rings; the side chains were then subjected to molecular mechanics and molecular dynamics calculations while restraining the binding pocket and the heterocyclic core; the temperature was ramped to 300 K over 10 ps, then held at 300 K for a further 20 ps. Once an optimal orientation had been established for the side-chains, the restraints were removed and the whole binding pocket (10 Å) was subjected to further molecular dynamics (20 ps at 300K) and then refined with mechanics calculations, allowing free movement of both the ligands and the binding pocket. Examples of illustrations generated by these calculations are shown in Figure 2 . As expected, each isoquinolin-1-one could make hydrogen bonds from the carbonyl oxygen to the side-chain O-H of Ser 904 and to the backbone N-H of Gly 863 . For example, in the minimised position for the most potent compound, 22g, this oxygen was located 2.25 Å from the latter and 1.59 Å from the former (Figure 2A ). The isoquinolin-1-one N-H was also located appropriately for a strong hydrogen bond to the backbone carbonyl of Gly 863 , as exemplified for 22g in Figure 2A with a distance of 2.08 Å. These hydrogen-bonding interactions are common in the modelled and co-crystal structures of inhibitors. It was also observed that the 5-NH 2 in these inhibitors was well accommodated within a small binding pocket and was orientated and located appropriately for a water-mediated hydrogen bond to the carboxylate of the important catalytic Glu 988 in the active site; an ordered water molecule is located in this position in several crystal structures. The core aromatic isoquinolin-1-one rings of 22a-k also formed a -stack with the electron-rich aromatic side-chain of Tyr 907 , as is common for PARP-1 inhibitors (illustrated for 22g in Figure 2B) . Notably, the bulk of the sulfur in 22f ( Figure 2C ) may possibly interfere with the critical hydrogen bond from the inhibitor N-H to Gly 863 of the enzyme, diminishing its potency.
These modelling studies indicated that the 3-substituents of 22a-k should occupy a hydrophobic pocket. Figure 2D shows the 3-methyl of 22g entering shallowly into this space, whereas the 3-(4-trifluoromethylphenyl) of 22a appears to fill the pocket ( Figure 2E ), reflecting the increased inhibitory potency of these and closely related compounds when compared with 4.
Conclusion
This paper reports a one-pot tandem Hurtley -retro-Claisen -cyclisation reaction sequence, which is useful in preparing 3-aryl and 3-alkyl 5-nitroisocoumarins 12. These are important intermediates in accessing the corresponding 3-aryl and 3-alkyl 5-aminoisoquinolin-1-ones 22. The tandem sequence can be carried out with either unsymmetrical or symmetrical -diketones. The whole preparation of the targets 22 is achieved without recourse to sealed tubes, particularly for the Hurtley step and for the isocoumarin-to-isoquinolinone step, which have previously required such specialised equipment. 32, 39 This new sequence tolerates most Many of the 3-substituted 5-AIQ derivatives 22a-k showed moderately more potent inhibition of the enzymatic activities of PARP-1 and PARP-2 than the parent 4, although there was no selectivity evident for either isoform. As demonstrated by molecular modelling, the 3-substituents entered a modestly-sized hydrophobic pocket in both enzymes. The ready access to these structures through the tandem Hurtley -retro-Claisen -cyclisation reaction sequence now enables further structure-activity studies for design and discovery of new inhibitors of these clinically important enzymes.
Experimental

Chemistry
Mps were determined using a Reichert-Jung Thermo Galen Kofler block and are uncorrected. IR spectra were recorded on a Perkin-Elmer RXI FT-IR spectrometer as KBr discs. NMR spectra were recorded on either a JEOL GX 270 (270. Mass spectra were obtained using a VG 7070 mass spectrometer. Column chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Experiments were conducted at ambient temperature, unless otherwise stated. Solutions in organic solvents were dried using anhydrous MgSO 4 and solvents were evaporated under reduced pressure. 
5-Nitro-3-(4-trifluoromethylphenyl)isocoumarin (12a
5-Nitro-3-(4-trifluoromethylphenyl)isocoumarin (12a) and 3-methyl-5-nitroisocoumarin (12g). Method B.
Compound 10 3 ). Further elution yielded 12g (40 mg, 6%) as yellow crystals, with data as below. yielded 12g (170 mg, 8%) as yellow crystals, with data as below.
5-Nitro-3-phenylisocoumarin (12b) and 3-methyl-5-nitroisocoumarin (12g
5-Nitro-3-phenylisocoumarin (12b). Method B.
Compound 10 34 (5.0 g, 20 mmol) and Cu powder (150 mg, 2.4 mmol) were added to 17b (22.9 g, 102 mmol) and KOBu t (4.6 g, 41 mmol) in Bu t OH (100 mL). The mixture was boiled under reflux for 16 h, then poured into water and acidified with aq. HCl (2 M). This suspension was extracted (Et 2 O). Evaporation and chromatography (hexane / EtOAc 10:1) gave 12b (4.2 g, 78%) as yellow crystals, with data as above.
3-(4-Methylphenyl)-5-nitroisocoumarin (12c).
Compound 10 
3-(4-Methoxyphenyl)-5-nitroisocoumarin (12d). Method B.
Compound 10 34 was treated with 17d, 43 Cu and KOBu t in Bu t OH, as for the synthesis of 12b (Method B) (chromatographic eluent: hexane / EtOAc 4:1) to give 12d (61%) as yellow crystals, with data as above. 
3-(4-Chlorophenyl)-5-nitroisocoumarin (12e
5-Nitro-3-pentylisocoumarin (12h). Method B.
Compound 10 34 was treated with 17h, 45 Cu and KOBu t in Bu t OH, as for the synthesis of 12b (Method B) to give 12h (36%) as a pale yellow oil, with data as above.
5-Nitro-3-phenylmethylisocoumarin (12i).
3-Ethyl-5-nitroisocoumarin (12j).
5-Nitro-3-(4-trifluoromethylphenyl)isoquinolin-1-one (21a).
Compound 12a (560 mg, 1.7 mmol) in MeO(CH 2 ) 2 OH (50 mL) was saturated with NH 3 and boiled under reflux for 4 h. The solvent and excess reagent were evaporated until 10 mL remained. 19. 3-(4-Methylphenyl)-5-nitroisoquinolin-1-one (21c) .
Compound 12c was treated with NH 3 in 2-methoxyethanol, as for the synthesis of 21a, to give 21c (86%) as bright yellow crystals: mp 175-176C; 1 
5-Nitro-3-(2-methylpropyl)isoquinolin-1-one (21k).
Compound 12k was treated with NH 3 in 2-methoxyethanol, as for the synthesis of 21a, to give 21k (89%) as bright yellow crystals: mp 184-185C; IR  max 3436, 1655, 1523, 1376 cm Compound 21a (1.0 g, 3.0 mmol) was heated at 70C with SnCl 2 (1.8 g, 9.5 mmol) in EtOH (50 mL) for 4 h, then poured into ice-H 2 O (200 mL). The suspension was made alkaline with aq. NaOH and filtered. Extraction of the filtrate (EtOAc), evaporation and recrystallisation (hexane / EtOAc) gave 22a (360 mg, 40%) as yellow crystals: mp 214-215C; IR  max 3419,
